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Abstract
Introduction
Insulin like growth factor (IGF)-I can act on a variety of cells involved in cartilage and bone
repair, yet IGF-I has not been studied extensively in the context of inflammatory arthritis.
The objective of this study was to investigate whether IGF-I overexpression in the osteo-
blast lineage could lead to increased reparative or pathological bone formation in rheuma-
toid arthritis and/or spondyloarthritis respectively.
Methods
Mice overexpressing IGF-I in the osteoblast lineage (Ob-IGF-I+/-) line 324–7 were studied
during collagen induced arthritis and in the DBA/1 aging model for ankylosing enthesitis.
Mice were scored clinically and peripheral joints were analysed histologically for the pres-
ence of hypertrophic chondrocytes and osteocalcin positive osteoblasts.
Results
90–100% of the mice developed CIA with no differences between the Ob-IGF-I+/- and non-
transgenic littermates. Histological analysis revealed similar levels of hypertrophic chondro-
cytes and osteocalcin positive osteoblasts in the ankle joints. In the DBA/1 aging model for
ankylosing enthesitis 60% of the mice in both groups had a clinical score 1<. Severity was
similar between both groups. Histological analysis revealed the presence of hypertrophic
chondrocytes and osteocalcin positive osteoblasts in the toes in equal levels.
Conclusion
Overexpression of IGF-I in the osteoblast lineage does not contribute to an increase in
repair of erosions or syndesmophyte formation in mouse models for destructive and remod-
eling arthritis.
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Introduction
Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are the two most frequent forms of
chronic inflammatory arthritis [1]. Both diseases are not only characterized by joint inflam-
mation but also by marked structural damage to bone, cartilage, and soft tissues leading
ultimately to loss of function of affected joints. The phenotype of the structural damage, how-
ever, is strikingly different between RA and SpA. RA is characterized by progressive destruc-
tion of cartilage and bone in the virtual absence of any repair and new bone formation, even
when inflammation is completely controlled. Whereas cartilage and bone destruction are
also important features of SpA, the structural phenotype is dominated by pathological new
bone formation eventually leading to complete ankylosis of the axial and/or peripheral joints
[2]. In physiological conditions, bone resorption and new bone formation are balanced and
tightly coupled processes. The molecularmechanisms of excessive bone erosion in inflamma-
tory arthritis are relatively well understood, with a central role for TNF and the receptor
activator of nuclear factor kappa-B ligand (RANKL) in the maturation and activation of oste-
oclasts [3]. Accordingly, blocking TNF and/or RANKL almost completely abrogates progres-
sion of bone erosions in experimental and human inflammatory arthritis [3]. Moreover, in
hTNF transgenic mice, TNF is able to suppress new bone formation during chronic inflam-
mation by up regulating DKK-1, an inhibitor of the wingless protein (Wnt) pathway [4].
These observations, however, fail to explain why bone repair is not occurring after inhibiting
inflammation in RA and why new bone formation does occur during active inflammation in
SpA [5–7]. A better understanding of which molecular pathways are involved in new bone
formation in the arthritic joints may help us to decipher and eventually modulate the struc-
tural phenotype of RA and SpA.
The most studiedmolecular pathways in osteogenesis during inflammatory arthritis are the
Wnt pathway [8] and the bone morphogenic protein (BMP) pathway [9], both of which are
important in driving chondro- and osteogenic cell differentiation. A third pathway, which has
not been studied extensively in the context of arthritis, is the insulin-like growth factor (IGF)-I
pathway [10, 11]. IGF-I is a growth factor acting on a variety of target cells, including chondro-
cytes and osteoblasts [12]. IGF-I can drive mesenchymal cells towards chondrocyte differentia-
tion [13], up regulate chondrocyte anabolism, and thereby enhance cartilage repair [14].
Moreover, IGF-I acts as chemoattractant for osteoblasts [15]. Its relevance of homeostatic bone
turnover is evidenced by the fact that serum levels of IGF-I correlate with bone formation and
bone resorptionmarkers [16] and levels drop in aging individuals [10]. As to arthritic condi-
tions, we showed previously that IGF-I is one of the major drivers of melanoma inhibitory
activity (MIA) expression, a biomarker of cartilage anabolism, in arthritis [17]. Furthermore an
IGF-I gene polymorphismwas found to relate to low serum IGF-I levels and RA severity [18].
Collectively, these findings indicate that IGF-I could be an important molecular player control-
ling new bone formation in inflammatory arthritis. Therefore, this study aimed to investigate
the potential role of IGF-I in repair of erosions and/or formation of syndesmophytes in experi-
mental models of RA and SpA, respectively, taking advantage of the Ob-IGF-I+/- mice [19].
These animals have osteoblast-lineage specific IGF-I overexpression under the rat collagen
type 1 alpha I promoter and display an increase in bone density and enhanced growth. Local
inflammation plays a center role in inflammatory arthritis, by studying IGF-I overexpression
under the osteoblast promotor, in this paper we specifically focus on inflammation induced
pathology in the joint at the local site of erosions in RA and pathological syndesmophyte for-
mation in SpA. We hypothesized that overexpression of IGF-I in the osteoblast lineage could
lead to an increase repair of erosions, typical for RA-like disease and/or to an increase in
pathology caused by syndesmophyte formation suggestive of SpA-like disease.
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Materials and Methods
Animal experiments were performed in accordance with the animal ethical committee Aca-
demicMedical Center/University of Amsterdam, Amsterdam, the Netherlands. Permit num-
bers DRI-102402 and DRI-102702. Mice were euthanised using compressed CO2 gas, first in
combination with O2 (70%/30% ratio) followed by 100% CO2. This study was approved by the
animal ethical committee Academic Medical Center/University of Amsterdam, Amsterdam,
the Netherlands.
Mice
Ob-IGF-I+/- mice (324–7) [19], kindly provided by Dr. B. Kream from the University of Con-
necticutHealth Center, were backcrossed for at least 10 generations on the genetic DBA/
1OlaHsd background. During all animal experiments efforts were made to minimize suffering.
Collagen induced arthritis
CIA was induced in Ob-IGF-I+/-transgenic mice and non-transgenic littermates (n = 9 males
per group) as described [20]. Mice were followed up for 60 days and sacrificed for histological
analysis. One wildtype was taken out of the study at day 52 due to reaching the humane end-
point for arthritis severity; last observationwas carried forward.
Ankylosing enthesitis DBA/1 aging model
Ob-IGF-I+/-transgenic mice and non-transgenic littermates (n = 15 males per group) from var-
ious litters were mixed and caged together at 10 weeks of age in standard cages (6 mice/cage),
mice were scored twice a week as describedbefore [21]. Mice were followed-up for 16 weeks
and sacrificed for histological analysis. Three mice were taken out of the study after 4–7 weeks
due to severe bite wounds; last observationwas carried forward.
Histology
From the 9 mice per group in the CIA experiment both ankles (n = 18) were used for histology,
6 out of 18 mice per group in the ankylosing enthesitis model had clinical disease and toes
from both feet were selected for histology (n = 12). Accordingly, bone tissues were fixed in
4% formalin, decalcified in EDTA or Osteosoft (Merck) and paraffin-embedded.5 μm serial
sections were cut and stained with Hematoxilin and Eosin, Safranin O (Sigma-Aaldrich) or
Tartrate Resistant Acid Phosphatase (TRAP) according to manufacturer’s instructions (Sigma-
Aaldrich) for ankle sections after CIA only. Ankle slides were semi-quantitatively scored for
inflammation, destruction, proteoglycan loss, presence of hypertrophic chondrocytes as a
measure for new bone formation and TRAP positive cells to indicate osteoclasts. Toes were
scored for hypertrophic chondrocytes. Scoring was performed by two independent blinded
observers (MvT, LvD) using a 0–3 scoring system (0 = no, 1 = mild, 2 = moderate 3 = severe
pathology).
Immunohistochemistry
Osteoblasts in ankle and toe sections were stained for osteocalcin, accordingly, antigen retrieval
was performedwith proteinase K at 37°C, followed by protein block and overnight incubation
at 4°C with 1 μg/ml rabbit-anti-mouse polyclonal osteocalcin antibody (#ALC-210-333 Enzo
life sciences) or 1 μg/ml rabbit Ig fractions isotype (DAKO). Slides were semi-quantitatively
scored by two independent blinded observers (MvT, LvD) using a 0–3 scoring system.
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Statistical analysis
Mann-Whitney U tests were performed using Graph pad Prism 5 software, for clinical data
area under the curvewas calculated followed by a Mann-Whitney U test. P values below 0.05
were considered statistically significant.
Results
Overexpression of IGF-I in the osteoblast lineage does not lead to bone
repair in CIA
To study the effect of IGF-I overexpression in the osteoblast lineage on joint repair in destruc-
tive arthritis, CIA was induced in Ob-IGF-I+/- mice and non-transgenic littermates. Disease
incidence and development were similar, with an incidence of 90% and 100% in non-trans-
genic mice and Ob-IGF-I+/- mice, respectively. Disease was equally severe (p = NS), arthritis
development started around 14–21 days after immunization with a mean arthritis score of 5–7
per mouse at day 60. (Fig 1A). Histologically, inflammatory infiltrates were present in syno-
vium, connective tissue, cartilage and bone in both groups. Joint destruction and erosions were
present in both groups as indicated by the overall destruction and proteoglycan loss in the
ankle sections (Fig 1B). Also the presence of hypertrophic chondrocytes in connective tissue
could be observed in both groups (Fig 1B). Quantification of histological features indicated a
similar degree of inflammation, cartilage and bone destruction, proteoglycan loss and hyper-
trophic chondrocytes suggestive for bone formation (p = NS) (Fig 1C). To confirm similar
presence of erosions a TRAP staining for osteoclasts was performed. TRAP positive osteoclasts
were mainly present near the site of pathology (Fig 1D), there were no differences in osteoclast
numbers between the Ob-IGF-I+/- mice and non-transgenic littermates (Fig 1E) To confirm
the absent effect of IGF-I overexpression on the repair of erosions, we additionally stained
osteocalcin positive osteoblasts in hind limb sections of all mice. As expected, osteocalcin posi-
tive osteoblast were mainly found near the periosteum; Isotype control staining was completely
negative (Fig 1F). Quantification indicated similar numbers of osteocalcin positive cells in Ob-
IGF-I+/- mice and non-transgenic littermates (p = NS) (Fig 1G). Taken together, these data
show that overexpression of IGF-I in the osteoblast lineage did not affect CIA, neither in terms
of clinical disease and inflammation nor in terms of structural phenotype in general and repair
of bone erosions in particular.
Overexpression of IGF-I in the osteoblast lineage does not enhance
pathological new bone formation in ankylosing enthesitis
As IGF-I did not appear to play a crucial role in the repair of bone eriosions in a model of
destructive inflammatory arthritis, we next tested if IGF-I overexpression increases the forma-
tion of syndesmophytes in remodeling arthritis using the DBA/1 aging model for ankylosing
enthesitis [22]. 10 week old Ob-IGF-I+/- mice and non-transgenic littermates (n = 15/group)
from various litters were mixed and housed together (6 mice/cage) [21]. Dactylitis and enthesi-
tis started 20 days after mixed caging and slowly progressed to a disease incidence of 70% in
both groups after 16 weeks of follow-up. Disease incidence and severity were comparable
between groups (p = NS) (2A). To investigate the potential role for IGF-I on syndesmophyte
formation, the presence of hypertrophic chondrocytes, detected by Safranin O staining, and
osteocalcin positive osteoblasts, was analyzed histologically after 16 weeks of clinical follow-up.
Hypertrophic chondrocytes were mainly found in the distal part of the toes surrounding the
small joints and were present in both groups, two of the IGF-I transgenic mice had hypertro-
phic chondrocytes in the toes and three of the non-transgenic littermates (Fig 2B and 2C).
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Fig 1. IGF-I overexpression does not lead to reparative bone remodeling in collagen induced arthritis. CIA was induced in Ob-
IGF-I+/- and controls (n = 9 per group). Arthritis incidence and severity were comparable (A). Severity is shown for diseased mice only.
Data are mean ± SEM. Representative pictures of ankle joints show inflammation, destruction, proteoglycan loss and hypertrophic
IGF-I and Bone Remodeling in Inflammatory Arthritis
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Based on Safranin O positive staining six slides per group were selected for osteocalcin staining.
Osteocalcin positive osteoblasts were found as expected near the periosteum (data not shown).
Quantification of osteocalcin positive osteoblasts in Ob-IGF-I+/- mice and non-transgenic lit-
termates revealed similar levels of positivity (p = NS) (Fig 2D). Thus, IGF-I overexpression did
not enhance syndesmophyte formation in the ankylosing enthesitis model.
chondrocytes (magnification respectively 50x, 100x, 100x and 100x; black arrows: inflammation, red arrow: destruction/proteoglycan
loss, white arrow: hypertrophic chondrocytes) (B) and quantification (C). TRAP positive osteoclasts detected in ankle sections
(magnification 100x) (D) and quantification of osteoclasts (E) Osteocalcin and isotype stained ankle sections (magnification 100x) (F)
and quantification of osteocalcin positive cells (G). Each data point represents one ankle, bars show median.
doi:10.1371/journal.pone.0163632.g001
Fig 2. IGF-I overexpression in osteoblasts does not affect new bone formation in the DBA/1 aging model for ankylosing enthesitis. Aging male
DBA/1 mice were followed up for 110 days and scored for spontaneous development of remodeling arthritis. Disease incidence and severity were
comparable in both groups (A). Severity is shown for diseased mice only. Data are mean ± SEM. Safranin O staining revealed in both groups healthy toes
(B) and toes with clear appearance of hypertrophic chondrocytes (C) (Magnification: 100x; white arrows point towards regions with hypertrophic
chondrocytes). Quantification of osteocalcin positive osteoblasts revealed no differences (D).
doi:10.1371/journal.pone.0163632.g002
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Discussion
In the present study we investigated the potential role of IGF-I in bone remodeling during
chronic joint inflammation in mice. Mice with IGF-I overexpression in the osteoblast lineage
show an increase in bone density under homeostatic conditions [19]. To test the hypothesis
that IGF-I overexpression could also contribute to repair of erosions in destructive arthritis, we
performedCIA experiments in mice overexpressing IGF-I in the osteoblast lineage. Our
results, however, indicated no differences in either clinical disease parameters or structural
phenotype between the Ob-IGF-I+/- mice and non-transgenic littermates, indicating that local
IGF-I overexpression, produced by activated osteoblasts, does not contribute to bone repair in
destructive arthritis.
Although the clinical and histological observationswere consistent in showing the absence
of effect, the data should be interpreted with caution and do not allow to conclude that IGF-I is
not important in destructive arthritis. Indeed, we mainly focused this study on repair of ero-
sions and did not assess whether or not IGF-I overexpression protects from peri-articularoste-
oporosis, a prominent feature of destructive arthritis such as RA. Moreover, we could not
assess if absence of IGF-I may accelerate local or systemic bone damage as IGF-I knockout
mice have a perinatal lethality of 95% [23]. Finally, we used here a model where IGF-I is
expressed under the rat collagen type 1 alpha I promoter in osteoblasts, implicating that IGF-I
will be strongly overexpressed upon activation of osteoblasts.We chose to use this model rather
than a constitutive overexpression model as it allows to study the role of IGF-I more specifi-
cally and physiologically during active bone turn-over. At young age Ob-IGF-I+/- males and
females from the 324–7 line have elevated serum IGF-I levels and a concomitant increase in
bodyweight during growth and development [19]. In the present CIA study, the Ob-IGF-I+/-
males show a significant increase in bodyweight compared to littermate controls (data not
shown) however the mice, fully grown adults, show no difference in systemic levels of IGF-I
compared to littermate controls (data not shown).
Therefore, we next hypothesized that IGF-I overexpression might enhance ongoing osteo-
blast-mediated syndesmophyte formation in SpA-like disease. To test this hypothesis we per-
formed an experiment using the same transgenic mouse strain in the DBA/1 aging model for
ankylosing enthesitis, where there is clear evidence of osteoblastic activity in the affected
entheses and joints [22]. Aging males from different litters were mixed and housed together to
induce continuous stress resulting in the spontaneous development of inflammation and anky-
losis in the peripheral joints. Again IGF-I transgenic mice show a significant increase in body-
weight compared to wildtype littermates (data not shown). Clinically we could not observe
differences between the two groups. Histologically we could not detect enhanced presence of
syndesmophytes as indicated by equal presence of hypertrophic chondrocytes and osteoblasts
in the Ob-IGF-I+/- mice and non-transgenic littermates. We can conclude that IGF-I overex-
pression in the osteoblast lineage did not contribute to enhanced syndesmophyte formation in
SpA-like disease.
We cannot exclude that the overexpression of IGF-I in both diseasemodels could, on top of
the phenotype of the IGF-I transgenic mice [19], could have subtle changes in bone and bone
density as there were no histomorphometric analyses performed.We were specifically inter-
ested in pathological processes induced locally and concerning the remodeling of bone during
inflammatory arthritis, either repair of erosions in RA or syndesmophyte formation in SpA.
For these analyses semi-quantitative scoring is sufficient in our experience.
The fact that transgenic mice in both experiments had higher bodyweight compared to lit-
termate controls indicates that the transgene was indeed operative. However we can obviously
not exclude that forced constitutive overexpression of IGF-I may affect bone metabolism in
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general and new bone formation in particular, we chose to focus on the local mode of action as
we were specifically interested in inflammation induced pathology occurring in the joints.
However our data indicate that the activation of osteoblasts and therefore the IGF-I axis in
both a destructive arthritis model and a remodeling ethesitis model is insufficient to promote
either repair of erosions or pathological syndesmophyte formation.
In conclusion, our experiments clearly and consistently indicate that IGF-I overexpression
in the osteoblast lineage does not contribute to enhancement of repair of bone erosions or syn-
desmophyte formation during experimental arthritis, although IGF-I has clearly a role in bone
metabolism, our data concord to indicate that it is not a major determinant of osteoprolifera-
tion in inflammatory arthritis. It needs to be emphasized, however, that a lot of other factors
are involved in the tightly regulated process of bone remodeling [3, 4, 8, 9]. We can thus not
exclude that, although IGF-I overexpression on its own has no effect on osteoproliferation, it
may enhance formation of new bone induced by other factors. Further research should identify
other growth factors and molecular pathways playing a more central role in the pathophysiol-
ogy of new bone formation during inflammatory arthritis.
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